Literature DB >> 11587555

Neuroendocrine tumor markers.

S W Lamberts1, L J Hofland, F R Nobels.   

Abstract

Tumor markers used in the diagnosis and follow-up of patients with neuroendocrine tumors are in most instances not specific for a given tumor and circulate under normal conditions in the serum, making their use as an early diagnostic tool difficult (low sensitivity). By combining hormone measurements with tissue responsiveness, demonstrations of inappropriate secretions of PTH, insulin, and gastrin during hypercalcemia, hypoglycemia, and hyperacidity, respectively, become highly sensitive and specific diagnostic tests. The application of polyclonal antibodies in RIAs of hormones, such as ACTH, insulin, and gastrin, increase the diagnostic level of hormone measurements in patients with neuroendocrine tumors. Other markers, such as chromogranin A, neuron-specific enolase, and alpha-subunit, as well as peptide receptor visualization, are of increasing importance in the diagnosis and follow-up of neuroendocrine and non-neuroendocrine tumors. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11587555     DOI: 10.1006/frne.2001.0218

Source DB:  PubMed          Journal:  Front Neuroendocrinol        ISSN: 0091-3022            Impact factor:   8.606


  21 in total

Review 1.  Mechanisms of storage and exocytosis in neuroendocrine tumors.

Authors:  Manfred Gratzl; Martin Breckner; Christian Prinz
Journal:  Endocr Pathol       Date:  2004       Impact factor: 3.943

Review 2.  Nanoparticle Probes for the Detection of Cancer Biomarkers, Cells, and Tissues by Fluorescence.

Authors:  Alyssa B Chinen; Chenxia M Guan; Jennifer R Ferrer; Stacey N Barnaby; Timothy J Merkel; Chad A Mirkin
Journal:  Chem Rev       Date:  2015-08-27       Impact factor: 60.622

Review 3.  Primary hepatic neuroendocrine tumor with multiple liver metastases: A case report with review of the literature.

Authors:  Kai Yang; Ying-Sheng Cheng; Ji-Jin Yang; Xu Jiang; Ji-Xiang Guo
Journal:  World J Gastroenterol       Date:  2015-03-14       Impact factor: 5.742

4.  Evaluation of chromogranin A determined by three different procedures in patients with benign diseases, neuroendocrine tumors and other malignancies.

Authors:  Rafael Molina; Elias Alvarez; Angeles Aniel-Quiroga; Maria Borque; Belen Candás; Antonio Leon; Rafael M Poyatos; Montserrat Gelabert
Journal:  Tumour Biol       Date:  2010-08-21

Review 5.  Less common neoplasms of the pancreas.

Authors:  Abby-L Mulkeen; Peter-S Yoo; Charles Cha
Journal:  World J Gastroenterol       Date:  2006-05-28       Impact factor: 5.742

Review 6.  The biological characterization of neuroendocrine tumors: the role of neuroendocrine markers.

Authors:  P Ferolla; A Faggiano; G Mansueto; N Avenia; M G Cantelmi; P Giovenali; M L Del Basso De Caro; F Milone; G Scarpelli; S Masone; F Santeusanio; G Lombardi; G Angeletti; A Colao
Journal:  J Endocrinol Invest       Date:  2008-03       Impact factor: 4.256

7.  Primary intracranial neuroendocrine tumor with ectopic adrenocorticotropic hormone syndrome: A rare and complicated case report and literature review.

Authors:  Hailong Liu; Mingshan Zhang; Xuan Wang; Yanming Qu; Hongwei Zhang; Chunjiang Yu
Journal:  Mol Clin Oncol       Date:  2016-05-11

8.  Long acting octreotide in the treatment of advanced hepatocellular cancer and overexpression of somatostatin receptors: randomized placebo-controlled trial.

Authors:  D Dimitroulopoulos; D Xinopoulos; K Tsamakidis; A Zisimopoulos; E Andriotis; D Panagiotakos; A Fotopoulou; C Chrysohoou; A Bazinis; D Daskalopoulou; E Paraskevas
Journal:  World J Gastroenterol       Date:  2007-06-21       Impact factor: 5.742

9.  Primary hepatic neuroendocrine tumor: A case report.

Authors:  Asahiro Morishita; Hirohito Yoneyama; Takako Nomura; Teppei Sakamoto; Koji Fujita; Joji Tani; Hisaaki Miyoshi; Reiji Haba; Tsutomu Masaki
Journal:  Mol Clin Oncol       Date:  2016-03-17

10.  Histone H1x is highly expressed in human neuroendocrine cells and tumours.

Authors:  Julia Warneboldt; Florian Haller; Olaf Horstmann; Bernhard C Danner; László Füzesi; Detlef Doenecke; Nicole Happel
Journal:  BMC Cancer       Date:  2008-12-24       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.